TRT and the Black Box Warning: What Changed in 2025

If you have ever looked at a testosterone product label, you may remember a prominent, boxed warning about cardiovascular risk. That warning, in place since 2015, was removed in February 2025 in one of the most significant regulatory shifts in the history of testosterone therapy (Healthline, 2025).

What Is a Black Box Warning?

A black box warning, formally called a boxed warning, is the FDA's strongest safety label. It signals that a drug carries a serious or life threatening risk and is meant to make prescribers think twice before writing a prescription. Many drugs with boxed warnings see prescribing rates drop sharply after the label change is announced.

For testosterone products, the warning specifically called out a possible increased risk of heart attack and stroke. It was added during a period of intense scrutiny following a small number of observational studies suggesting cardiovascular harm.

Why the FDA Changed Course

The 2025 update was driven primarily by the results of the TRAVERSE trial, a large randomized controlled study that followed thousands of men on testosterone gel or placebo for nearly three years. The trial found that major cardiovascular events occurred at similar rates in both groups: 7.0 percent on testosterone versus 7.3 percent on placebo (HealthSpectra TRAVERSE summary).

TRAVERSE was specifically designed to settle the cardiovascular question that earlier observational studies had raised. Because randomized trials are the gold standard for determining cause and effect, the results gave the FDA confidence that the boxed warning was no longer justified by the science.

What the Label Says Now

The updated label still mentions cardiovascular considerations, but no longer in boxed form. Patients with a recent heart attack, stroke, or unstable cardiovascular disease are still advised to discuss the risks with their physician. The change is essentially a downgrade: from a strong, prominent warning to a more standard precaution.

What This Means for Patients

For patients, the practical effect is that physicians may be more willing to consider TRT for appropriate candidates, and insurance reviewers may face fewer barriers to authorizing therapy. It does not mean TRT is risk free. The therapy still carries known side effects including polycythemia, acne, fertility suppression, and sleep apnea worsening.

The change is best understood as a recalibration: the earlier warning, based on weaker evidence, was probably too strong, and the new label better reflects what high quality clinical research actually shows.

Looking Ahead

The label change was followed in December 2025 by an FDA expert panel recommending even broader access reforms, including a possible end to testosterone's classification as a controlled substance (RAPS, 2025). Then in April 2026, the FDA opened the door to a new approved indication for low libido in idiopathic hypogonadism (Federal Register, 2026).

Together, these developments represent the most patient friendly regulatory environment for TRT in more than a decade. If you are ready to find a qualified provider who stays current with these regulatory changes, our TRT Locator directory can help.

Frequently Asked Questions

Was the TRT black box warning fully removed?

Yes. In February 2025, the FDA removed the cardiovascular black box warning from testosterone product labels. Cardiovascular considerations are still mentioned in the labeling, but no longer in the prominent boxed format that signals serious or life-threatening risk.

Why was the black box warning added to testosterone products in the first place?

The warning was added in 2015 following a period of intense regulatory scrutiny after several observational studies suggested a possible link between TRT and heart attacks and strokes. Observational studies cannot prove causation, but the FDA acted on the concern at the time by adding the warning.

What evidence led the FDA to remove the warning?

The primary driver was the TRAVERSE trial, a large randomized controlled study of more than 5,000 men that found no statistically significant difference in major cardiovascular events between men on testosterone and men on placebo. Randomized trials are considered stronger evidence than the observational studies that triggered the original warning.

Does removing the black box warning mean TRT is risk-free?

No. TRT still carries known side effects including polycythemia (elevated red blood cell count), worsened sleep apnea, fertility suppression, acne, and potential prostate effects. Patients with recent heart attacks, strokes, or unstable cardiovascular disease should still discuss therapy carefully with their physician.

Will this regulatory change make it easier to get TRT approved by insurance?

Likely yes for some patients. The black box warning contributed to conservative prescribing and cautious insurance review. With it removed, physicians may feel more comfortable initiating therapy for appropriate candidates, and insurance reviewers may face fewer internal barriers to authorizing it.

Sources

• FDA Panel: Expanded Access to TRT (Healthline)
• TRAVERSE Trial: Heart Safety of TRT (HealthSpectra)
• FDA Panel Calls for Easing TRT Restrictions (RAPS)

Find a TRT clinic near you →